Evidence map›Paper›PMID 40195239›Full record

ArticleTranslational stroke research2025

Hyperthermia and Early Growth of Cerebral Infarct: The Potential Role of Blood-Brain Barrier Permeability.

Crhistian-Mario Oblitas, Ana Sampedro-Viana, Sabela Fernández-Rodicio, Manuel Rodríguez-Yáñez, Iria López-Dequidt, Arturo Gonzalez-Quintela, Antonio J Mosqueira, Jacobo Porto-Álvarez, Javier Martínez Fernández, Marcos Bazarra-Barreiros and 9 more

Abstract read
In one paragraph

Article in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Crhistian-Mario OblitasNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain. crhistian.mario.amodeo.oblitas@sergas.es.
Ana Sampedro-VianaNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Sabela Fernández-RodicioNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Manuel Rodríguez-YáñezStroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, 15706, A Coruña, Spain.
Iria López-DequidtDepartment of Neurology, Hospital Clínico Universitario de Ferrol, Ferrol, 15405, A Coruña, Spain.
Arturo Gonzalez-QuintelaDepartment of Internal Medicine, Hospital Clínico Universitario, Santiago de Compostela, 15706, A Coruña, Spain.
Antonio J MosqueiraNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Jacobo Porto-ÁlvarezDepartment of Neuroradiology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Javier Martínez FernándezDepartment of Neuroradiology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Marcos Bazarra-BarreirosNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
María Teresa Abengoza-BelloNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Sara Ortega-EspinaNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Alberto OuroNeuroaging Laboratory Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Francisco CamposTranslational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Tomás SobrinoNeuroaging Laboratory Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
José CastilloNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Maria Luz Alonso-AlonsoNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Pablo HervellaNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain.
Ramón Iglesias-ReyNeuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, A Coruña, Spain. ramon.iglesias.rey@sergas.es.

Funding

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CB22/05/00067Instituto de Salud Carlos III CM23/00173Instituto de Salud Carlos III CP14/00154Instituto de Salud Carlos III CPII17/00027Instituto de Salud Carlos III FI22/00200Instituto de Salud Carlos III PI17/01103, PI22/00938, ISCIII/PI21/01256Ministerio de Ciencia e Innovación SAF2017-84267-RPOCTEP 0624_2IQBIONEURO_6_EXunta de Galicia IN607A2022-03, IN607A2022/07
6 · The paper itself

Abstract

Hyperthermia within the first 24 h following ischemic stroke (IS) has been associated with poor outcomes. We sought to determine whether blood-brain barrier (BBB) permeability contributes to the relationship between hyperthermia and early infarct growth (EIG). A retrospective analysis was conducted on a prospective stroke biobank. EIG was defined as the percentage difference between the initial volume (mL) determined by the diffusion-weighted imaging at admission and the volume (mL) from the control CT image on the 4 th-7 th day. Hyperthermia was defined as an axillary body temperature ≥ 37.5 °C within the first 24 h. Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) serum levels were measured by ELISA. One-hundred and two (19.7%) patients showed EIG from a cohort of 519 patients (45.6% females). Linear correlation was observed for axillar body temperature and EIG (Pearson's r = 0.46; p < 0.001). sTWEAK serum levels showed a c-statistic of 0.74 (95% CI: 0.69-0.79), with an optimal cut-off point > 3000 pg/mL for EIG prediction. Moreover, microalbuminuria levels strongly correlated with sTWEAK levels (Pearson's r = 0.75; p < 0.001). In the multivariate analysis for EIG was observed an independent association with hyperthermia (adjusted OR 24.21; 95% CI: 12.03-39.12), sTWEAK levels > 3000 pg/mL (adjusted OR 16.43; 95% CI: 3.71-72.70), leukoaraiosis (adjusted OR 10.42; 95% CI: 2.68-39.08), and microalbuminuria (adjusted OR 1.02; 95% CI: 1.00-1.12). In our cohort, hyperthermia was independently associated with EIG after IS. The fact that microalbuminuria, leukoaraiosis, and sTWEAK were also associated with EIG suggests a relationship with increased BBB permeability.

Indexed as

Blood-Brain BarrierCerebral InfarctionHyperthermiaAgedAged, 80 and overCapillary PermeabilityCytokine TWEAKFemaleHumansMaleMiddle AgedRetrospective StudiesCytokine TWEAKTNFSF12 protein, humanBlood–brain barrierEarly infarct growthHyperthermiaMicroalbuminuriasTWEAK

Identifiers

PMID40195239
PMCPMC12391183

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.